CINECA IRIS Institutional Research Information System

VALERIO, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.191
EU - Europa 2.386
AS - Asia 2.238
SA - Sud America 332
AF - Africa 179
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.337
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.078
IT - Italia 774
SG - Singapore 719
CN - Cina 601
DE - Germania 528
SE - Svezia 341
HK - Hong Kong 332
BR - Brasile 270
VN - Vietnam 185
GB - Regno Unito 178
BG - Bulgaria 131
FR - Francia 100
RU - Federazione Russa 86
CI - Costa d'Avorio 77
JP - Giappone 76
IN - India 75
AT - Austria 68
CA - Canada 66
TR - Turchia 60
FI - Finlandia 45
SN - Senegal 42
BD - Bangladesh 34
MA - Marocco 27
NL - Olanda 24
MX - Messico 23
PK - Pakistan 20
PL - Polonia 20
IQ - Iraq 19
AR - Argentina 18
KR - Corea 18
IR - Iran 15
ZA - Sudafrica 14
PH - Filippine 13
UZ - Uzbekistan 12
VE - Venezuela 12
ID - Indonesia 11
SA - Arabia Saudita 11
UA - Ucraina 11
BE - Belgio 9
CO - Colombia 9
EC - Ecuador 9
AU - Australia 8
CZ - Repubblica Ceca 8
ES - Italia 8
GR - Grecia 8
CR - Costa Rica 7
CH - Svizzera 6
UY - Uruguay 6
EG - Egitto 5
IE - Irlanda 5
PA - Panama 5
PT - Portogallo 5
RO - Romania 5
AL - Albania 4
CL - Cile 4
KZ - Kazakistan 4
LT - Lituania 4
NG - Nigeria 4
TN - Tunisia 4
TW - Taiwan 4
AZ - Azerbaigian 3
BH - Bahrain 3
GT - Guatemala 3
HU - Ungheria 3
IL - Israele 3
JO - Giordania 3
LB - Libano 3
MY - Malesia 3
SK - Slovacchia (Repubblica Slovacca) 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
HN - Honduras 2
IS - Islanda 2
KG - Kirghizistan 2
MM - Myanmar 2
MT - Malta 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
EE - Estonia 1
GA - Gabon 1
JM - Giamaica 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.337
Salva come PNG Salva come JPEG
Città #
Ashburn 570
Singapore 395
Hong Kong 324
Chandler 323
Dallas 320
Milan 292
Fairfield 258
San Jose 255
Santa Clara 236
Woodbridge 169
Houston 147
Seattle 134
Shanghai 130
Sofia 130
Wilmington 121
New York 118
Beijing 111
Los Angeles 101
Cambridge 96
Abidjan 77
Munich 74
Princeton 72
Ann Arbor 66
Vienna 62
London 61
Boardman 60
Tokyo 60
Ho Chi Minh City 55
Frankfurt am Main 53
Lauterbourg 52
Lawrence 51
Rome 51
Dakar 42
Florence 42
Medford 38
Pisa 34
Serra 31
Redwood City 30
Boulder 29
Council Bluffs 25
Dong Ket 25
Ottawa 25
São Paulo 25
Buffalo 22
Dearborn 22
Hanoi 22
Istanbul 22
Redmond 22
San Diego 22
Bremen 21
Helsinki 20
Redondo Beach 20
Washington 19
Hefei 18
Des Moines 17
Montreal 16
Phoenix 16
Fuzhou 14
Nuremberg 14
Belo Horizonte 13
Orem 13
Turku 13
Amsterdam 12
Scandicci 12
Baghdad 11
Casablanca 11
Dhaka 11
Toronto 11
Atlanta 10
Chiesina Uzzanese 10
Guangzhou 10
Nanjing 10
Quanzhou 10
Tashkent 10
Tianjin 10
Warsaw 10
Chicago 9
Denver 9
Düsseldorf 9
Izmir 9
Mumbai 9
San Francisco 9
Seoul 9
Zhengzhou 9
Brasília 8
Haiphong 8
Lancaster 8
Nanchang 8
Salt Lake City 8
Boston 7
Brussels 7
Roubaix 7
San José 7
Shenyang 7
Shenzhen 7
Columbus 6
Dublin 6
Jiaxing 6
Johannesburg 6
Kocaeli 6
Totale 6.048
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 243
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 239
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 233
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 233
Targeted Therapy in Thyroid Cancer: State of the Art 224
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 223
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 219
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 217
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 214
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 213
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 211
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 208
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 207
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 205
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 203
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 196
Il carcinoma tiroideo: nuove prospettive terapeutiche. 191
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 190
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 189
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 188
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 177
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 177
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 177
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 171
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 171
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 170
Role of oxidative stress in radio-induced DNA damage and in RET/PTC rearrangement in papillary thyroid cancer 164
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 164
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 161
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 161
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 156
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 154
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 152
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 150
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 150
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 149
Prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma: 10-year impact on surgical and oncologic outcomes 143
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 138
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 137
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 136
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 136
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 133
FDG-PET/CT Correlates with the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival 129
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 128
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 127
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer 126
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 121
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 118
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 117
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 112
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 103
Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study 102
Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination 90
null 84
Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer 67
Fifty Years after the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases 54
Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study) 3
Totale 9.493
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.750
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.750
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202172 0 0 0 0 0 0 0 0 0 0 0 72
2021/2022607 16 14 14 25 132 83 14 27 39 37 46 160
2022/20231.221 162 187 90 89 110 124 27 98 232 14 79 9
2023/2024922 91 118 133 85 144 154 29 20 10 11 44 83
2024/20252.031 11 65 22 120 212 214 163 88 196 255 188 497
2025/20262.519 227 356 270 213 292 167 387 112 181 217 83 14
Totale 9.493